Era Biotech, S.a.

Zera Intein Protein Solutions, S.l.

François Devesa

Edward Peter Rybicki

Ann Elizabeth Meyers

Inga Isabel Hitzeroth

Pablo Marzábal Luna

Peter Öhlschläger

Peter ÖHLSCHLÄGER

Edwar Peter Rybicki

An immunogen-specific is adjuvant for a vaccine or inoculum is disclosed. The adjuvant is comprised of particulate recombinant protein body-like assemblies (RPBLAs) that contain a recombinant fusion protein that contains two portions peptide-linked together. A first portion is a protein body-inducing sequence (PBIS) and a second portion is a T-cell stimulating immunogenic polypeptide whose sequence is that of a pathogenic polypeptide sequence present in or induced by a vaccine or inoculum. The adjuvant, when used as an inoculum in a host animal without a prior priming vaccination or inoculation, does not induce production of antibodies or T cell activation to the pathogenic sequence.

Recombinant protein bodies as immunogen-specific adjuvants

Growing community of inventors

Launaguet, France

François Devesa